NASDAQ:CLLS - Cellectis Stock Price, Forecast & News

Cellectis trades on the NASDAQ under the ticker symbol "CLLS."

Cellectis SA (NASDAQ:CLLS) announced its quarterly earnings data on Tuesday, August, 6th. The biotechnology company reported ($0.79) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.61) by $0.18. The biotechnology company earned $2.93 million during the quarter, compared to the consensus estimate of $3.45 million. Cellectis had a negative net margin of 446.75% and a negative return on equity of 21.03%. View Cellectis' Earnings History.

Cellectis is scheduled to release their next quarterly earnings announcement on Wednesday, March 4th 2020. View Earnings Estimates for Cellectis.

Cellectis will be holding an earnings conference call on Wednesday, March 4th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

6 equities research analysts have issued 1 year price targets for Cellectis' shares. Their forecasts range from $20.00 to $73.00. On average, they expect Cellectis' share price to reach $40.80 in the next twelve months. This suggests a possible upside of 157.6% from the stock's current price. View Analyst Price Targets for Cellectis.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cellectis in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cellectis.

News articles about CLLS stock have trended very negative this week, according to InfoTrie. The research group identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Cellectis earned a coverage optimism score of -3.2 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 4.0 out of 10, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next few days. View News Stories for Cellectis.

Cellectis saw a increase in short interest in February. As of February 14th, there was short interest totalling 261,800 shares, an increase of 15.4% from the January 30th total of 226,800 shares. Based on an average daily trading volume, of 130,300 shares, the short-interest ratio is currently 2.0 days. Approximately 0.6% of the company's stock are short sold. View Cellectis' Current Options Chain.

Some companies that are related to Cellectis include Fate Therapeutics (FATE), Denali Therapeutics (DNLI), Alector (ALEC), Bill.com (RVMD), Regenxbio (RGNX), SpringWorks Therapeutics (SWTX), Cortexyme (CRTX), Coherus Biosciences (CHRS), NanoString Technologies (NSTG), Editas Medicine (EDIT), Beam Therapeutics (BEAM), Twist Bioscience (TWST), Orchard Therapeutics (ORTX), BAVARIAN NORDIC/S (BVNRY) and I-Mab (BDTX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Cellectis investors own include Calyxt (CLXT), NVIDIA (NVDA), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Exelixis (EXEL), Editas Medicine (EDIT), WEC Energy Group (WEC), Micron Technology (MU), Neurocrine Biosciences (NBIX) and Portola Pharmaceuticals (PTLA).

(CLLS) raised $129 million in an initial public offering (IPO) on Wednesday, March 25th 2015. The company issued 3,500,000 shares at $36.83 per share. BofA Merrill Lynch, Jefferies and Piper Jaffray served as the underwriters for the IPO and Oppenheimer was co-manager.

Cellectis' stock is owned by many different of retail and institutional investors. Top institutional investors include FMR LLC (7.50%), ARK Investment Management LLC (3.16%), Nikko Asset Management Americas Inc. (3.01%), Sumitomo Mitsui Trust Holdings Inc. (3.01%), Capital International Investors (2.39%) and Credit Suisse AG (1.09%).

CLLS stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Point72 Asset Management L.P., Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., UBS Group AG, Cubist Systematic Strategies LLC, Victory Capital Management Inc. and Eqis Capital Management Inc..

CLLS stock was bought by a variety of institutional investors in the last quarter, including Capital International Investors, Rhenman & Partners Asset Management AB, ARK Investment Management LLC, Capital Asset Advisory Services LLC, Geode Capital Management LLC, Atria Investments LLC, OneAscent Financial Services LLC and Granite Point Capital Management L.P..

Shares of CLLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CLLS stock can currently be purchased for approximately $15.84.

Cellectis has a market capitalization of $672.41 million and generates $21.43 million in revenue each year. The biotechnology company earns $-78,690,000.00 in net income (profit) each year or ($1.93) on an earnings per share basis. Cellectis employs 161 workers across the globe.View Additional Information About Cellectis.

The official website for Cellectis is http://www.cellectis.com/.

Cellectis' mailing address is 8 RUE DE LA CROIX JARRY, PARIS I0, 75013. The biotechnology company can be reached via phone at 33-1-81-69-16-00 or via email at [email protected]